首页> 外文期刊>Journal of Cancer Research and Therapeutics >Comparison of clinical outcomes after thoracoscopic sublobectomy versus lobectomy for Stage I nonsmall cell lung cancer: A meta-analysis
【24h】

Comparison of clinical outcomes after thoracoscopic sublobectomy versus lobectomy for Stage I nonsmall cell lung cancer: A meta-analysis

机译:胸腔镜肺叶切除术与肺叶切除术治疗I期非小细胞肺癌的临床结局比较:一项荟萃分析

获取原文
       

摘要

Background: Although lobectomy has long been considered the standard procedure for Stage I nonsmall cell lung cancer (NSCLC), the selection of sublobectomy for Stage I NSCLC remains controversial. Amidst growing enthusiasm for minimally invasive surgery, the comparison of clinical outcomes after thoracoscopic sublobectomy versus thoracoscopic lobectomy may be of immense value. Objective: The present study aimed to compare the overall survival (OS) and disease-free survival (DFS) outcomes of patients who underwent thoracoscopic sublobectomy with those who underwent thoracoscopic lobectomy for Stage I NSCLC. Methods: An electronic search was conducted using five online databases from their dates of inception to February 2014. Hazard ratio (HR) was used in this meta-analysis, calculated from the published survival data. Results: Eight studies met the selection criteria, including a total of 1613 patients (463 patients underwent thoracoscopic sublobectomy, and 1150 patients underwent thoracoscopic lobectomy). From the available data, compared with thoracoscopic sublobectomy, there was a significant benefit of thoracoscopic lobectomy on OS (HR: 1.45; 95% confidence interval [CI]: 1.11–1.90; P = 0.007). However, in subgroup analysis of thoracoscopic segmentectomy and thoracoscopic lobectomy, there was no significant difference in OS (HR: 1.03; 95% CI: 0.76–1.39; P = 0.85) or DFS (HR: 1.19; 95% CI: 0.67–2.10; P = 0.56) between the two groups. In addition, compared with thoracoscopic wedge resection, there was a significant benefit of thoracoscopic lobectomy on OS (HR: 4.19; 95% CI: 2.19–8.03, P Conclusion: For Stage I patients, thoracoscopic segmentectomy leads to survival rates comparable to thoracoscopic lobectomy. However, the overall several of thoracoscopic lobectomy is superior to that of wedge resection.
机译:背景:尽管长期以来人们一直认为肺叶切除术是I期非小细胞肺癌(NSCLC)的标准程序,但对于I期NSCLC的亚肺叶切除术的选择仍存在争议。随着对微创手术的热情不断提高,胸腔镜下肺叶切除术与胸腔镜下肺叶切除术的临床结局比较可能具有巨大的价值。目的:本研究旨在比较接受胸腔镜肺叶切除术和接受胸腔镜肺叶切除术治疗I期NSCLC患者的总生存期(OS)和无病生存期(DFS)。方法:从成立之日至2014年2月,使用五个在线数据库进行了电子搜索。在该荟萃分析中使用了危险比(HR),该比值是根据已发布的生存数据计算得出的。结果:八项研究符合选择标准,包括总共1613例患者(463例接受了胸腔镜肺叶切除术,而1150例接受了胸腔镜肺叶切除术)。从现有数据来看,与胸腔镜肺叶切除术相比,胸腔镜肺叶切除术对OS有显着益处(HR:1.45; 95%置信区间[CI]:1.11-1.90; P = 0.007)。但是,在胸腔镜节段切除术和胸腔镜肺叶切除术的亚组分析中,OS(HR:1.03; 95%CI:0.76-1.39; P = 0.85)或DFS(HR:1.19; 95%CI:0.67-2.10)没有显着差异。 ; P = 0.56)。此外,与胸腔镜楔形切除相比,胸腔镜肺叶切除术对OS有显着益处(HR:4.19; 95%CI:2.19–8.03,P结论:对于I期患者,胸腔镜肺段切除术的生存率与胸腔镜肺叶切除术相当但是,整体胸腔镜肺叶切除术要优于楔形切除术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号